Illumina and Optum Genomics Clinical Catalyst Program
Illumina and Optum Genomics Clinical Catalyst Program supports developers of emerging genomic tests with clinical evidence assessment and access planning to help bring promising applications into patient care.
Funder: Illumina
Due Dates:
Funding Amounts:
Summary: The program helps developers of emerging genomic applications assess clinical evidence and plan for patient access.
Key Information: The program focuses on clinical applications developed using Illumina technology.
Description
Launched in 2022, the Clinical Catalyst Program is a collaboration between Illumina and Optum Genomics to identify and accelerate emerging genomic applications that could improve patient care and health outcomes. It focuses on promising clinical applications developed using Illumina technology.
The program evaluates evidence for a test’s clinical validity and clinical utility, then supports evidence planning for clinical readiness and patient access. It also examines whether an application has a clear intended use and value proposition for payer discussions, with the aim of helping developers communicate clinical value and pursue more effective market access strategies.
